Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Slides:



Advertisements
Similar presentations
Brown JR et al. Proc ASH 2013;Abstract 523.
Advertisements

Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
Dyer MJS et al. Proc ASH 2014;Abstract 1743.
1 Flinn I et al. Proc ICML 2013;Abstract 084.
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
CCO Independent Conference Highlights
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.
Treatment of early-stage Hodgkin lymphoma
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
Andrzej Jakubowiak  Seminars in Hematology 
Clinical Lymphoma, Myeloma and Leukemia
The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma  Kyung Ah Yoh, Ho Sup Lee,
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal.
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Acupuncture versus Sham Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain  Shaun Wen Huey Lee, MPharm, Men Long Liong, MD, Kah Hay Yuen, PhD, Wing.
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study 
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.
R-CHOP for Frontline Follicular Lymphoma
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report  Ivana N.
Jonathan W. Friedberg M.D., M.M.Sc.
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,
by Michael F. Leahy, and J. Harvey Turner
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,
Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission  Quoc Truong,
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma  Pallawi Torka, Priyank Patel, Wei Tan,
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab.
Follicular lymphoma Every patient should be treated at diagnosis
David J. Tunnicliffe, Suetonia C. Palmer 
Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review  Trent P. Wang, Steven G.
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience  AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I  Ruben A. Mesa, Srdan Verstovsek,
Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic.
Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis  Moussab.
Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France  Nicolas Despiégel, Chantal Touboul, Alain.
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker  Manuela Giachelia, Valentina Bozzoli,
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review  Denise M.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma  John M. Burke,
Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions  Antoinette I.M. van Laarhoven, Ineke M. van der.
Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature 
Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075)  Juan C. Ramos, Joseph A. Sparano,
Yousef Rezaei, MD  American Journal of Kidney Diseases 
A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer  Christopher.
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I  Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,
Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides  Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker 
Volume 381, Issue 9880, Pages (May 2013)
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson 
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice  Abdalla Awidi, Salah Abbasi,
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review  Jill A. Bell, Aaron.
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target    American.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma  Adrian J.C. Bloor, Kirsty.
CR-rate ratios with 95% CIs
by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Optimizing therapy for nodal marginal zone lymphoma
Catheter Type, Placement, and Insertion Techniques for Preventing Catheter-Related Infections in Maintenance Peritoneal Dialysis Patients: Summary of.
Presentation transcript:

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma  John M. Burke, Richard H.C. van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Mihaela Munteanu, Timothy W. Victor, Ian W. Flinn  Clinical Lymphoma, Myeloma and Leukemia  Volume 16, Issue 4, Pages 182-190.e1 (April 2016) DOI: 10.1016/j.clml.2016.01.001 Copyright © 2016 The Authors Terms and Conditions

Figure 1 CONSORT Diagram of Patient Disposition. *Efficacy-Evaluable Treated Patients who Have a Baseline and at Least One Post-Baseline Efficacy Evaluation, or who Discontinued Due to Progressive Disease and Did Not Have Major Protocol Violations. Republished With Permission From the American Society of Hematology, From Flinn IW, et al. Randomized Trial of Bendamustine-Rituximab or R-CHOP/R-CVP in First-Line Treatment of Indolent NHL or MCL: the BRIGHT Study. Blood 2014; 123; Permission Conveyed Through Copyright Clearance Center, Inc Abbreviations: AE = Adverse event; BR = bendamustine and rituximab; PD = progressive disease; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP = rituximab, cyclophosphamide, vincristine, and prednisone. Clinical Lymphoma, Myeloma and Leukemia 2016 16, 182-190.e1DOI: (10.1016/j.clml.2016.01.001) Copyright © 2016 The Authors Terms and Conditions

Figure 2 EORTC QLQ-C30 Domain Scores Forest Plot Comparing BR With R-CHOP/R-CVP (Difference). Horizontal Bars Represent Standard Error; • Shows Statistical Significance, P < .05 ANCOVA; x Shows Statistical Significance Over a Portion of the Range (Outside of the Listed Bounds), by Johnson-Neyman Analysis Abbreviations: ANCOVA = Analysis of covariance; BR = bendamustine-rituximab; JN = Johnson-Neyman analysis; JN+ = bendamustine-rituximab superior in a portion of the range; JN± = bendamustine-rituximab superior for a portion of the range, while the comparator treatments superior for another portion of the range. Clinical Lymphoma, Myeloma and Leukemia 2016 16, 182-190.e1DOI: (10.1016/j.clml.2016.01.001) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Johnson-Neyman Analysis of Fatigue. The Best Fit Lines in the End of Cycle 3 and End of Cycle 6 Plots Are Separated and Parallel, Indicating that Fatigue Was Less With BR (Solid Line) Compared With Standard Therapy (Dashed Line) at These Time Points. However, the Best Fit Lines in the End of Cycle 1 Plot Were Not Parallel. In This Situation, a Johnson-Neyman Analysis Was Used. The Shaded Area Below a Score of 48.8 Indicates that, in Patients With Low Levels of Fatigue at Baseline, There Was No Statistically Significant Difference Between the Groups in Level of Fatigue at the End of Cycle 1; in Contrast, in Patients With Higher Levels of Fatigue at Baseline, Treatment With BR Resulted in a Lower Level of Fatigue Compared With Standard Therapy at the End of Cycle 1 Abbreviations: BR = bendamustine-rituximab; CI = confidence interval. Clinical Lymphoma, Myeloma and Leukemia 2016 16, 182-190.e1DOI: (10.1016/j.clml.2016.01.001) Copyright © 2016 The Authors Terms and Conditions